Another SGLT-2 Diabetes Drug Cuts CV Risks

CV after-effects trials at ADA contend with favor canagliflozin but bland for insulins

Cardiovascular faces in type 2 diabetes were thin with use of canagliflozin (Invokana) but not augmented with insulin degludec, corresponding to divided FDA-mandated cardiovascular trick trials articled at the American Diabetes Exchangeable with meeting in San Diego.

In the CANVAS (Canagliflozin Cardiovascular Assessment Mull over) program, the sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin fact at 100 or 300 mg every day downgraded the exceptional endpoint of act, non-fatal myocardial infarction (MI), and cardiovascular eradication correlated with placebo, with a shy characteristic of 26.9 versus 31.5 partakings per 1,000 patient-years (HR 0.86, P<0.001 for noninferiority and P=0.02 for greatness).